A phase 2 randomised, open-label, multi-centre ascending dose study of the efficacy, safety and tolerability of I-040302 versus control injection (bone marrow aspirate or steroids) in children and young adults with solitary bone cysts.
Withdrawn prior to enrolment
Phase of Trial: Phase II
Latest Information Update: 26 Feb 2017
At a glance
- Drugs KUR 112 (Primary) ; Methylprednisolone
- Indications Bone cysts
- Focus Therapeutic Use
- 16 Jul 2012 Status changed from not yet recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
- 15 Mar 2012 Planned initiation date changed from 1 Dec 2011 to 1 Dec 2012 as reported by ClinicalTrials.gov.
- 15 Mar 2012 Planned end date changed from 1 Jul 2018 to 1 Jul 2019 as reported by ClinicalTrials.gov.